重症监护中更新的「去甲肾上腺素等效」评分作为休克严重程度的标志物
本文综述了去甲肾上腺素等效(NEE)评分的历史与临床应用。当前国际休克指南推荐去甲肾上腺素为一线升压药、血管加压素为二线升压药;临床实践中因药物可及性、当地实践差异、特殊场景及在研研究,会在缺乏精确等效剂量时使用多种替代升压药和辅助药。NEE常用于临床试验以标准化描述升压药支持,可作为入选标准和结局指标。NEE存在若干缺陷,尤其是未纳入血管紧张素II等新型升压药和亚甲蓝等辅助药,且缺乏高质量数据支持该方程并在所有类型重症监护实践中验证其预测性能。本综述描述了NEE的历史,并提出纳入新型升压药和辅助药的更新公式。
要点
- 当前国际休克指南推荐去甲肾上腺素为一线升压药、血管加压素为二线升压药。
- NEE量化升压药总量时考虑每种药物效力,通常包括儿茶酚胺、衍生物和血管加压素。
- NEE在重症研究中用作入选标准和结局指标。
- NEE的缺陷包括未纳入血管紧张素II等新型升压药和亚甲蓝等辅助药。
- NEE缺乏高质量数据支持方程并在所有类型重症监护实践中验证预测性能。
适用人群与场景
- 重症监护中接受升压药治疗的休克患者
- 临床试验中使用NEE作为入选标准或结局指标的人群
处置流程与药物剂量
- 当前国际休克指南推荐去甲肾上腺素作为一线升压药。
- 当前国际休克指南推荐血管加压素作为二线升压药。
研究设计与关键结果
- 综述描述了NEE的历史,并提出纳入新型升压药和辅助药的更新公式。
- NEE量化升压药总量时考虑每种药物效力,通常包括儿茶酚胺、衍生物和血管加压素。
- NEE的缺陷包括未转换血管紧张素II等新型升压药和亚甲蓝等辅助药,以及缺乏高质量数据支持方程并在所有类型重症监护实践中验证预测性能。
证据类型、等级与局限
- 证据类型:综述。
- 局限:缺乏高质量数据支持NEE方程并在所有类型重症监护实践中验证其预测性能。
对床旁实践的改变
- 作者提出更新公式以纳入新型升压药和辅助药。
- 临床医生应了解NEE的缺陷,尤其是未纳入血管紧张素II和亚甲蓝等药物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Vasopressors and fluids are the cornerstones for the treatment of shock. The current international guidelines on shock recommend norepinephrine as the first-line vasopressor and vasopressin as the second-line vasopressor. In clinical practice, due to drug availability, local practice variations, special settings, and ongoing research, several alternative vasoconstrictors and adjuncts are used in the absence of precise equivalent doses. Norepinephrine equivalence (NEE) is frequently used in clinical trials to overcome this heterogeneity and describe vasopressor support in a standardized manner. NEE quantifies the total amount of vasopressors, considering the potency of each such agent, which typically includes catecholamines, derivatives, and vasopressin. Intensive care studies use NEE as an eligibility criterion and also an outcome measure. On the other hand, NEE has several pitfalls which clinicians should know, important the lack of conversion of novel vasopressors such as angiotensin II and also adjuncts such as methylene blue, including a lack of high-quality data to support the equation and validate its predictive performance in all types of critical care practice. This review describes the history of NEE and suggests an updated formula incorporating novel vasopressors and adjuncts.
参考来源
- Kotani Y, Di Gioia A, Landoni G, et al. An updated "norepinephrine equivalent" score in intensive care as a marker of shock severity. Crit Care. 2023. PMID: 36670410. doi:10.1186/s13054-023-04322-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。